Masimo announced U.S. Food and Drug Administration 510(k) clearance for the Root patient monitoring and connectivity platform. The platform includes a built-in connectivity gateway through Iris for ...
Now Available for Both Cerebral and Somatic Applications and for All Patient Populations, O3’s Delta Hemoglobin Parameters Offer Clinicians Additional Insight Into Changes in Tissue Oxygen Saturation ...
Irvine, California-based Masimo, makers of a suite of non-invasive patient monitoring devices and sensors, has expanded the capabilities of its connected platform to allow physicians to view more data ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the results of a prospective, observational study published in Critical Care in which researchers in Genoa, Italy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results